Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression

Andrew Krystal, Maurizio Fava, Robert Rubens, Thomas Wessel, Judy Caron, Phebe Wilson, Thomas Roth, William Vaughn McCall

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Background: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. Methods: Patients meeting DSM-IV criteria for MDD and insomnia received fluoxetine each morning for 8 weeks and were randomized to concomitant treatment with nightly eszopiclone 3mg (cotherapy) or placebo (monotherapy). Thereafter, patients received 2 weeks of continued fluoxetine plus single-blind placebo. Results: Incidence rates of central nervous system (CNS) and potentially CNS-related adverse events (AEs) during the run-out period were similar between treatment groups (8.8% with monotherapy vs 9.8% with cotherapy), and there was no evidence of benzodiazepine withdrawal AEs. Physician-assessed Clinical Global Impression improvements in depressive symptoms were maintained after eszopiclone discontinuation. Improvements in 17-item Hamilton-Depression Rating Scale (HAM-D-17) scores with cotherapy versus monotherapy seen at Week 8 (p= .0004) were maintained at Week 10 (p< .0001) and significantly higher depression response and remission rates were observed after cotherapy at Week 10 (p< .02). Patients discontinued from eszopiclone maintained improvements in SL (sleep latency), WASO (wake after sleep onset), and TST (total sleep time) during the 2 weeks following discontinuation (P< 05). Conclusions: In this study, eszopiclone discontinuation did not result in significant CNS or benzodiazepine withdrawal AEs, rebound insomnia, or rebound depression; and improvements in sleep and depressive symptoms were maintained.

Original languageEnglish (US)
Pages (from-to)48-55
Number of pages8
JournalJournal of Clinical Sleep Medicine
Volume3
Issue number1
StatePublished - Feb 15 2007

Fingerprint

Fluoxetine
Sleep Initiation and Maintenance Disorders
Depression
Major Depressive Disorder
Sleep
Central Nervous System
Placebos
Benzodiazepines
Hypnotics and Sedatives
Diagnostic and Statistical Manual of Mental Disorders
Eszopiclone
Physicians
Incidence
Therapeutics

Keywords

  • Eszopiclone
  • Fluoxetine
  • Insomnia
  • Major depressive disorder
  • Rebound
  • Withdrawal

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Neurology
  • Clinical Neurology

Cite this

Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. / Krystal, Andrew; Fava, Maurizio; Rubens, Robert; Wessel, Thomas; Caron, Judy; Wilson, Phebe; Roth, Thomas; McCall, William Vaughn.

In: Journal of Clinical Sleep Medicine, Vol. 3, No. 1, 15.02.2007, p. 48-55.

Research output: Contribution to journalArticle

Krystal, A, Fava, M, Rubens, R, Wessel, T, Caron, J, Wilson, P, Roth, T & McCall, WV 2007, 'Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression', Journal of Clinical Sleep Medicine, vol. 3, no. 1, pp. 48-55.
Krystal, Andrew ; Fava, Maurizio ; Rubens, Robert ; Wessel, Thomas ; Caron, Judy ; Wilson, Phebe ; Roth, Thomas ; McCall, William Vaughn. / Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. In: Journal of Clinical Sleep Medicine. 2007 ; Vol. 3, No. 1. pp. 48-55.
@article{c1a484074e064a9ea4ef0d220e4a696f,
title = "Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression",
abstract = "Background: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. Methods: Patients meeting DSM-IV criteria for MDD and insomnia received fluoxetine each morning for 8 weeks and were randomized to concomitant treatment with nightly eszopiclone 3mg (cotherapy) or placebo (monotherapy). Thereafter, patients received 2 weeks of continued fluoxetine plus single-blind placebo. Results: Incidence rates of central nervous system (CNS) and potentially CNS-related adverse events (AEs) during the run-out period were similar between treatment groups (8.8{\%} with monotherapy vs 9.8{\%} with cotherapy), and there was no evidence of benzodiazepine withdrawal AEs. Physician-assessed Clinical Global Impression improvements in depressive symptoms were maintained after eszopiclone discontinuation. Improvements in 17-item Hamilton-Depression Rating Scale (HAM-D-17) scores with cotherapy versus monotherapy seen at Week 8 (p= .0004) were maintained at Week 10 (p< .0001) and significantly higher depression response and remission rates were observed after cotherapy at Week 10 (p< .02). Patients discontinued from eszopiclone maintained improvements in SL (sleep latency), WASO (wake after sleep onset), and TST (total sleep time) during the 2 weeks following discontinuation (P< 05). Conclusions: In this study, eszopiclone discontinuation did not result in significant CNS or benzodiazepine withdrawal AEs, rebound insomnia, or rebound depression; and improvements in sleep and depressive symptoms were maintained.",
keywords = "Eszopiclone, Fluoxetine, Insomnia, Major depressive disorder, Rebound, Withdrawal",
author = "Andrew Krystal and Maurizio Fava and Robert Rubens and Thomas Wessel and Judy Caron and Phebe Wilson and Thomas Roth and McCall, {William Vaughn}",
year = "2007",
month = "2",
day = "15",
language = "English (US)",
volume = "3",
pages = "48--55",
journal = "Journal of Clinical Sleep Medicine",
issn = "1550-9389",
publisher = "American Academy of Sleep Medicine",
number = "1",

}

TY - JOUR

T1 - Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression

AU - Krystal, Andrew

AU - Fava, Maurizio

AU - Rubens, Robert

AU - Wessel, Thomas

AU - Caron, Judy

AU - Wilson, Phebe

AU - Roth, Thomas

AU - McCall, William Vaughn

PY - 2007/2/15

Y1 - 2007/2/15

N2 - Background: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. Methods: Patients meeting DSM-IV criteria for MDD and insomnia received fluoxetine each morning for 8 weeks and were randomized to concomitant treatment with nightly eszopiclone 3mg (cotherapy) or placebo (monotherapy). Thereafter, patients received 2 weeks of continued fluoxetine plus single-blind placebo. Results: Incidence rates of central nervous system (CNS) and potentially CNS-related adverse events (AEs) during the run-out period were similar between treatment groups (8.8% with monotherapy vs 9.8% with cotherapy), and there was no evidence of benzodiazepine withdrawal AEs. Physician-assessed Clinical Global Impression improvements in depressive symptoms were maintained after eszopiclone discontinuation. Improvements in 17-item Hamilton-Depression Rating Scale (HAM-D-17) scores with cotherapy versus monotherapy seen at Week 8 (p= .0004) were maintained at Week 10 (p< .0001) and significantly higher depression response and remission rates were observed after cotherapy at Week 10 (p< .02). Patients discontinued from eszopiclone maintained improvements in SL (sleep latency), WASO (wake after sleep onset), and TST (total sleep time) during the 2 weeks following discontinuation (P< 05). Conclusions: In this study, eszopiclone discontinuation did not result in significant CNS or benzodiazepine withdrawal AEs, rebound insomnia, or rebound depression; and improvements in sleep and depressive symptoms were maintained.

AB - Background: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. Methods: Patients meeting DSM-IV criteria for MDD and insomnia received fluoxetine each morning for 8 weeks and were randomized to concomitant treatment with nightly eszopiclone 3mg (cotherapy) or placebo (monotherapy). Thereafter, patients received 2 weeks of continued fluoxetine plus single-blind placebo. Results: Incidence rates of central nervous system (CNS) and potentially CNS-related adverse events (AEs) during the run-out period were similar between treatment groups (8.8% with monotherapy vs 9.8% with cotherapy), and there was no evidence of benzodiazepine withdrawal AEs. Physician-assessed Clinical Global Impression improvements in depressive symptoms were maintained after eszopiclone discontinuation. Improvements in 17-item Hamilton-Depression Rating Scale (HAM-D-17) scores with cotherapy versus monotherapy seen at Week 8 (p= .0004) were maintained at Week 10 (p< .0001) and significantly higher depression response and remission rates were observed after cotherapy at Week 10 (p< .02). Patients discontinued from eszopiclone maintained improvements in SL (sleep latency), WASO (wake after sleep onset), and TST (total sleep time) during the 2 weeks following discontinuation (P< 05). Conclusions: In this study, eszopiclone discontinuation did not result in significant CNS or benzodiazepine withdrawal AEs, rebound insomnia, or rebound depression; and improvements in sleep and depressive symptoms were maintained.

KW - Eszopiclone

KW - Fluoxetine

KW - Insomnia

KW - Major depressive disorder

KW - Rebound

KW - Withdrawal

UR - http://www.scopus.com/inward/record.url?scp=34248599004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248599004&partnerID=8YFLogxK

M3 - Article

C2 - 17557453

AN - SCOPUS:34248599004

VL - 3

SP - 48

EP - 55

JO - Journal of Clinical Sleep Medicine

JF - Journal of Clinical Sleep Medicine

SN - 1550-9389

IS - 1

ER -